PHAR on Nasdaq

Pharming Group N.V.

Pharming Group N.V. is a pharmaceutical preparations company, listed on Nasdaq (PHAR).1

Price unavailable

Last updated Oct 20, 2026.

Overview

$2.5MNet income, fiscal 20252

Compare with another stock.

  • TickerPHAR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersP71
  • Incorporated inNetherlands3
  • Business addressDarwinweg 24, Leiden, P7 2333 Cr3
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

We were incorporated as a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) under the laws of the Netherlands on November 11, 1988 under the name GENFARM B.V. On May 29, 1997, the Company was converted from a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) into a public company (naamloze vennootschap) named Pharming Holding N.V. Effective July 2, 1998, Pharming Holding N.V. was renamed Pharming Group N.V.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

0.9%Return on equity2
$54.0MFree cash flow2

Financial statements

Gross profit56782$330.6M in 2025+100% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $165.5M$165.5M20192020: $188.6M$188.6M2020+14%2021: $177.7M$177.7M2021−6%2022: $188.1M$188.1M2022+6%2023: $220.1M$220.1M2023+17%2024: $261.8M$261.8M2024+19%2025: $330.6M$330.6M2025+26%
Operating income56782$25.8M in 2025−62% since 2019
-$25.0M0$25.0M$50.0M$75.0M$100.0M2019: $68.2M$68.2M20192020: $76.3M$76.3M2020+12%2021: $13.6M$13.6M2021−82%2022: $18.2M$18.2M2022+34%2023: -$5.4M-$5.4M20232024: -$8.6M-$8.6M2024+60%2025: $25.8M$25.8M2025
Net income56782$2.5M in 2025−94% since 2019
-$20.0M0$20.0M$40.0M$60.0M2019: $40.6M$40.6M20192020: $37.7M$37.7M2020−7%2021: $16.0M$16.0M2021−58%2022: $13.7M$13.7M2022−15%2023: -$10.5M-$10.5M20232024: -$11.8M-$11.8M2024+12%2025: $2.5M$2.5M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenues$376.1M$297.2M$245.3M
Costs of sales-$45.5M-$35.4M-$25.2M
Gross profit$330.6M$261.8M$220.1M
Other income$6.5M$2.2M$23.3M
Research and development-$100.4M-$83.1M-$68.9M
General and administrative-$80.0M-$70.7M-$55.9M
Marketing and sales-$131.0M-$118.8M-$124.0M
Other Operating Costs-$311.3M-$272.6M-$248.8M
Operating profit / (loss)$25.8M-$8.6M-$5.4M
Fair value gain (loss) on revaluation$2.3M$5.0M-$930.0K
Other finance income$2.2M$6.8M$3.7M
Other finance expenses-$18.1M-$9.9M-$9.1M
Finance (cost) / gain, net-$13.6M$1.9M-$6.3M
Share of net profits / (loss) in associates using the equity method$623.0K-$1.8M-$289.0K
Profit / (loss) before tax$12.8M-$8.5M-$12.0M
Income tax (expense) / credit-$10.3M-$3.3M$1.5M
Profit / (loss) for the year$2.5M-$11.8M-$10.5M
Equity holders of the parent$2.9M-$11.8M-$10.5M
Non-controlling interests-$313.0K$0$0
Basic (loss) / earnings per share (in usd per share)$0.00-$0.02-$0.02
Diluted (loss) / earnings per share (in usd per share)$0.00-$0.02-$0.02

Compare Pharming Group N.V. with another company

Corporate structure

Pharming Group N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Pharming Group N.V.

  • Morgan Stanley Filed SCHEDULE 13G/A on Pharming Group N.V., latest Apr 7, 2025 (2 filings since Nov 8, 2024)
  • RTW INVESTMENTS, LP Filed SC 13G/A on Pharming Group N.V., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • Pharming Group N.V. P7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Pharming Group N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$7.2M2 Dec 31, 2025$7.8M2 Dec 31, 2024−6.7%
Operating-lease assets (leased space)$16.7M2 Dec 31, 2025$16.4M2 Dec 31, 2024+2.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$145.3M2 Dec 31, 2025$54.9M2 Dec 31, 2024+164.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$135.5M2 Dec 31, 2025$61.0M2 Dec 31, 2024+122.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$64.9M2 Dec 31, 2025$55.7M2 Dec 31, 2024+16.5%

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.10 a share, on Nov 6, 2025.10

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

106 filings to the SEC since October 2021: 6 annual reports, 4 large holders, 96 other. The latest 20:

  1. Oct 14, 20266-K EDGAR
  2. Sep 29, 20266-K EDGAR
  3. Sep 25, 20266-K EDGAR
  4. Sep 22, 20266-K EDGAR
  5. Sep 11, 20266-K EDGAR
  6. Aug 13, 20266-K EDGAR
  7. Jul 30, 20266-K EDGAR
  8. Jun 4, 20266-K EDGAR
  9. May 28, 20266-K EDGAR
  10. May 22, 20266-K EDGAR
  11. May 7, 20266-K EDGAR
  12. May 7, 20266-K EDGAR
  13. Apr 16, 20266-K EDGAR
  14. Apr 13, 202620-F/A EDGAR
  15. Apr 2, 20266-K EDGAR
  16. Apr 2, 202620-F EDGAR
  17. Mar 27, 20266-K EDGAR
  18. Mar 24, 20266-K EDGAR
  19. Mar 12, 20266-K EDGAR
  20. Feb 3, 20266-K EDGAR

The 106 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
MAC Alpha Capital Management, LP2,148,144$2.9M1.4%New
Silverberg Bernstein Capital Management LLC41,547$577.1K0.2%−3,200
Crossmark Global Holdings, Inc.12,463$169.0K0.0%New
Citadel Advisors LLC11,972$162.3K0.0%+1,783
Morgan Stanley11,500$159.7K0.0%+11
SmartHarvest Portfolios, LLC10,415$144.7K0.0%−382
Knoll Capital Management, LLC4,091$56.8K0.0%+34
Silver Grove Financial Group, Inc.1,071$14.9K0.0%New
Nalls Sherbakoff Group, LLC870$12.1K0.0%No change
Global Retirement Partners, LLC456$6.3K0.0%New
Integrated Wealth Concepts LLC380$5.3K0.0%New
Bnp Paribas Financial Markets300$4.2K0.0%−100
Optiver Holding B.V.305$4.1K0.0%New
NewEdge Advisors, LLC187$2.6K0.0%−1,963
UBS Group AG39$5420.0%New
Osaic Holdings, Inc.16$2220.0%−112
Larson Financial Group LLC7$970.0%−336
Caitong International Asset Management Co., Ltd1$140.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Pharming Group N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPharming Group N.V.1
  • CIK0001828316
  • Filer statusAccelerated filer not an emerging growth company; not a shell company4
  • Incorporated inNetherlands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressDarwinweg 24, Leiden, P7 2333 CR1
  • Phone31 (0)71 5247 4001
  • Shares outstanding701,680,440 shares as of Dec 31, 20254
  • AuditorDeloitte Accountants B.V., Eindhoven, the Netherlands PCAOB ID 1243; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceOct 14, 20201
  • Filings146 in all: 6-K (115), 20-F (6), CORRESP (4), EFFECT (2), F-1/A (2), SC 13G (2), SEC STAFF LETTER (2), UPLOAD (2)1
    All 19 form types

    20-F/A (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-6 (1), S-8 (1), SC 13G/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Apr 2, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing ten ordinary shares, nominal value EUR 0.01 per sharePHARThe Nasdaq Stock Market LLC
Ordinary shares, nominal value EUR 0.01 per sharePHARThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Apr 2, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12